The 2023 American Diabetes Association consensus statement recommends SGLT-2is or GLP1-RA as a first-line agent (above metformin) in T2D patients with established or high cardio-renal risks [20]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.